MedTrace Logo

Specified Drug-use Survey of Leqvio for s.c. Injection.

NCT06275724 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 585

Last updated 2026-05-22

No results posted yet for this study

Summary

The objective of this study is to evaluate the long-term safety of Leqvio in patients with familial hypercholesterolaemia or hypercholesterolaemia in post-marketing clinical practice

Conditions

  • Familial Hypercholesterolaemia
  • Hypercholesterolaemia

Interventions

OTHER

inclisiran

Prospective observational study. There is no treatment allocation. Patients prescribed with inclisiran are eligible to enroll into this study.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
15 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-04
Primary Completion
2026-12-17
Completion
2026-12-17

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06275724 on ClinicalTrials.gov